Acadia Healthcare (ACHC) Stock Forecast & Price Target

Acadia Healthcare Co is viewed positively because its acute inpatient psychiatric facilities and broader behavioral health platform benefit from structurally strong demand, diversified service lines, and an expansive geographic footprint in a fragmented market. The company’s 1Q26 EBITDA upside was driven by stronger-than-expected volume growth, while management raised full-year adjusted EBITDA guidance to $580M-$615M and operating cash flow to $285M-$325M, supported by same-facility volume growth of 1%-2% and a 3.9x-4.2x year-end leverage ratio. The outlook is further reinforced by improving operational discipline, ramping newly added facilities, potential Florida DPP upside, and the expectation that one-time PLGL expense, startup losses, and denial-related pressure will ease, lifting 2027 EBITDA estimates.

Acadia Healthcare Co is facing a deteriorating operating backdrop, with management and the excerpted thesis both pointing to worsening performance before improvement, driven by higher clinical costs, labor tightness, and persistent payer-denial pressure. The company’s financial quality also looks fragile because free cash flow may not improve meaningfully as start-up losses fade and capital spending declines, while acute and specialty disruptions, weather-related EBITDA drag of $3.7M in 1Q26, and a 6.6% specialty revenue decline underscore uneven execution. Meanwhile, legal liabilities, investigations, reimbursement risk, and market concentration across a small number of states create hard-to-underwrite downside that could compress valuation even if same-facility admissions rose 6.5% y/y.